Nelip (Atorvastatin)

Atorvastatin, the active ingredient in Nelip, is a HMG‑CoA reductase inhibitor presented as an oral tablet for systemic use. It lowers elevated cholesterol and triglyceride levels and is prescribed for patients with hypercholesterolemia, mixed dyslipidemia, or those at risk of cardiovascular events.

GNH USA supplies Nelip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Nelip is manufactured in accordance with EU GMP guidelines, ensuring consistent potency and purity across batches.

Atorvastatin is employed to treat lipid disorders and to lower cardiovascular risk in appropriate patient groups. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol and total cholesterol levels. - Mixed dyslipidemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol while decreasing LDL. - Cardiovascular risk reduction: helps prevent myocardial infarction, stroke and other atherosclerotic events in patients with established risk factors.

Atorvastatin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Muscle aches or weakness - Elevated liver enzymes - Abdominal discomfort or nausea - Headache - Dizziness

Serious or Rare Side Effects: - Rhabdomyolysis with possible renal failure - Severe hepatic injury or hepatitis - Anaphylactic or severe allergic reactions - Myopathy with marked CK elevation - Acute pancreatitis

When prescribing atorvastatin, clinicians should observe several safety considerations to minimize risk. - Liver function monitoring: obtain baseline transaminases and repeat periodically. - Muscle symptom assessment: educate patients to report unexplained muscle pain, tenderness or weakness. - Drug interaction review: avoid concomitant use of strong CYP3A4 inhibitors and fibrates where possible. - Renal impairment caution: adjust therapy in patients with severe renal dysfunction. - Pregnancy and lactation: discontinue if pregnancy is confirmed or if breastfeeding, as safety data are limited. - Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat.

Atorvastatin interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole, ketoconazole): may cause marked increase in atorvastatin levels. - Gemfibrozil or high‑dose niacin: heightens risk of myopathy and rhabdomyolysis. - Cyclosporine or tacrolimus: significantly raises statin exposure. - HIV protease inhibitors (e.g., ritonavir): potentiate statin concentrations.

Moderate Interactions (Monitor Closely): - Antacids and H2‑blockers: may modestly affect absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: slight increase in serum levels reported. - Calcium channel blockers (e.g., amlodipine): can raise statin levels modestly. - Grapefruit juice: may increase exposure; advise limited consumption.